# Pizarra — PT-pseudo_562159dc2cc6 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.23   (95% CI 0.06-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.21  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 2.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=0.0, psa=9.9, age=48.0, psad=0.19, dre_ord=0.0, vol=50.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.31 ng/mL/yr) against the PI-RADS score of 2, which is a key dynamic factor. It also could not incorporate the history of fluctuating PSA values (first documented at 9.3 ng/mL in early 2024) or the specific context of the DRE being "Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done," which is ambiguous.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.43 +/- 0.23), indicating high uncertainty. A failure mode is the low PI-RADS score (2) conflicting with a high current PSA (9.9 ng/mL) and a rising PSA velocity (0.31 ng/mL/yr). Another failure mode is the prior biopsy status being 'None', which means the decision hinges entirely on the current imaging and labs, potentially overlooking the significance of the PSA trend.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic lesions despite PI-RADS 2, it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid recent increase, it would increase the suspicion level despite the low PI-RADS score.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the fluctuating PSA values or LUTS severity, which could inform the clinical significance of the current findings.
  <document> laboratory results (full panel) -> This panel might provide context on PSA density or other markers that modify the interpretation of the PI-RADS score.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_562159dc2cc6", "radiology_report": "Subject: Prostate MRI | Spaarne Gasthuis, Haarlem | 20 January 2025\nClinical Query: Persistent PSA elevation (9.9 ng/mL) and prior scoring.\nFINDINGS:\nVolumetric assessment yields a gland size of 50.0 mL. T2-weighted sequences reveal a homogeneous peripheral zone, lacking focal signal drops or diffusion restriction on ADC maps. Mild nodular hyperplasia characterizes the transition zone, aligning with benign enlargement. Dynamic contrast phases exhibit no early or focal enhancement patterns. Seminal vesicles maintain normal caliber and signal intensity. There is no evidence of extraprostatic spread or suspicious nodal disease.\nIMPRESSION:\nBenign prostatic enlargement measuring 50.0 mL. No PI-RADS 3 or higher lesion identified. PI-RADS 2.\nPSA density: 0.19 ng/mL/mL.\ncsPCa predicted probability 0.6607788."}

  **psa_trend**
  {"case_id": "PT-pseudo_562159dc2cc6", "psa_trend": [{"date": "Feb 2024", "val": 2.9}, {"date": "Aug 2024", "val": 4.9}, {"date": "Jan 2025", "val": 9.9}]}

  **previous_notes**
  {"case_id": "PT-pseudo_562159dc2cc6", "previous_notes": [{"date": "03 Feb 2024", "author": "Dr. R. Visser (GP)", "text": "Initial laboratory screening in February 2024 flagged a PSA reading of 9.3 ng/mL, which triggered a repeat draw and urology referral. Follow-up values temporarily decreased to 6.7 ng/mL during August, before climbing back to 9.9 ng/mL. The most recent multiparametric MRI scans and updated chemistry panel have been dispatched for specialist assessment."}]}

  **lab_results**
  {"case_id": "PT-pseudo_562159dc2cc6", "laboratory_results": [{"name": "PSA", "val": "9.9 ng/mL", "date": "28 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.76 ng/mL", "date": "28 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "28%", "date": "28 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.6 g/dL", "date": "28 Dec 2024", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "263 x10^9/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "92 umol/L", "date": "28 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "28 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "17.2 nmol/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "71 U/L", "date": "28 Dec 2024", "flag": ""}, {"name": "LDH", "val": "245 U/L", "date": "28 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.8 %", "date": "28 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PSA: 9.9 ng/mL (Current high value)
  PSA velocity: 0.31 ng/mL/yr (Rising trend)
  Previous notes: History of fluctuating PSA values, including a peak of 9.3 ng/mL, suggesting disease progression.
  Lab results: %Free PSA is 28% (which is generally reassuring, though context is needed).

  AGAINST sampling this patient now:
  mpMRI: PI-RADS score of 2 (Low risk).
  mpMRI: No evidence of extraprostatic spread or suspicious nodal disease.
  mpMRI: Impression states "No PI-RADS 3 or higher lesion identified."

WHERE THIS LEANS
  The evidence is conflicted: the clinical data (high PSA, rising trend, history of prior high PSA) suggests increased suspicion, while the imaging (PI-RADS 2) is reassuring. This contradicts the statistical prior of 'NO BIOPSY' by introducing dynamic clinical factors that the prior missed.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

Deferring biopsy is the recommended course because the imaging is reassuring with a PI-RADS 2 score and no suspicious findings. However, the decision is borderline due to the high current PSA of 9.9 ng/mL and a rising PSA velocity of 0.31 ng/mL/yr, which contradicts the low-risk imaging. The clinical context of fluctuating prior PSA values also increases suspicion, but without a PI-RADS 3 or higher lesion, repeating the biopsy adds risk without clear diagnostic gain.

Variables that carried weight: dre=noted, psa=important, vol=noted, psad=noted, pirads=noted, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
